Central America is a unique geographical region that connects North and South America, enclosed by the Caribbean Sea to the East, and the Pacific Ocean to the West. This region, encompassing Belize, Costa Rica, Guatemala, El Salvador, Honduras, Panama, and Nicaragua, is highly vulnerable to the emergence or resurgence of mosquito-borne and tick-borne diseases due to a combination of key ecological and socioeconomic determinants acting together, often in a synergistic fashion. Of particular interest are the effects of land use changes, such as deforestation-driven urbanization and forest degradation, on the incidence and prevalence of these diseases, which are not well understood. In recent years, parts of Central America have experienced social and economic improvements; however, the region still faces major challenges in developing effective strategies and significant investments in public health infrastructure to prevent and control these diseases.
1. Introduction
Vector-borne diseases (VBDs) remain an important public health problem worldwide, particularly in tropical and subtropical regions, and they are becoming more prevalent in recent years. Arthropod vectors are associated with the transmission of some of the most significant infectious diseases affecting both animals and humans
[1][2][3][1,2,3]. The global burden of VBDs is significant, accounting for more than 17% of infectious diseases in humans with more than three billion people currently inhabiting endemic areas and at risk of exposure to these pathogens
[4]. Most people affected by these diseases live in developing countries under conditions that favor a greater burden of disease, especially in poor and marginalized populations, including rural inhabitants, Indigenous populations, women living in poverty, the elderly, and children
[5][6][5,6]. Together, these diseases produce significant mortality and morbidity, causing millions of deaths every year, long-term disabilities, and life-long sequelae
[5][7][8][9][5,7,8,9].
Emerging and resurging diseases are defined as recently evolved or newly discovered pathogens that have demonstrated increased incidence in host populations in the past 20 years or poses a future threat. These pathogens are characterized by their expanding geographic spread, increasing public health impact, changes in their clinical presentation, or novel infection occurrence in humans
[10][11][10,11]. Some of these pathogens are also characterized by their resurgence after long periods of decline in infection incidence. About 60% of these diseases are zoonotic in origin and, to various degrees, dependent on animal reservoirs for survival and maintenance
[10][11][12][13][14][10,11,12,13,14]. In many countries, the incidence of these diseases has declined to low levels due mostly to effective prevention and control programs; however, some were never satisfactorily controlled throughout their endemic regions. Many are currently increasing in incidence and spreading beyond their previously known geographical ranges. Some of them have reappeared only in limited regions while others have become major global problems
[9][12][15][9,12,15].
Most emerging zoonotic VBDs are transmitted by ticks (Family
Ixodidae) and mosquitoes (
Culicidae) and caused by RNA viruses (Families
Flaviviridae,
Bunyaviridae, and
Togaviridae) and Rickettsiaceae bacteria
[12][16][12,16]. The vectorial capacity of mosquitoes and ticks is enhanced by their high environmental adaptability, which includes high reproductive outputs under suitable conditions and high capacity to invade ecologically disturbed environments, especially peridomestic habitats where human and domesticated animal hosts are readily available
[16][17][18][16,17,18]. In terms of human morbidity and mortality, malaria, dengue, Rickettsial fevers, and Lyme disease are some of the most important of these resurgent infections
[2][15][16][19][2,15,16,19].
The relationship between arthropod vectors and the pathogens they transmit is particularly sensitive to anthropogenically driven global changes. Factors behind the dramatic emergence and resurgence of VBDs are complex, vary geographically and temporarily, and often have an additive effect on disease ecology and epidemiology
[1][2][12][16][19][1,2,12,16,19]. Currently recognized anthropogenic drivers of VBD emergence and resurgence include demographic changes (e.g., global population movements and growth, unplanned and uncontrolled urbanization), socioeconomic changes (e.g., modern transportation and commerce, human encroachment on natural disease foci), illegal activities (e.g., illegal logging and cattle ranching, illegal drug trafficking), accelerated exploitation of natural resources (e.g., changes in land use, forest degradation, reduction in biodiversity, agricultural practices), changes in host susceptibility and pathogen adaptation (e.g., increased movement of humans and animals, pathogen genetic variability), degradation of public health infrastructure (e.g., lack of effective vector control, disease surveillance, and prevention programs), and climate change (e.g., changes in regional temperature and rainfall patterns lead to alterations in vector dynamics)
[1][2][12][16][19][20][21][22][1,2,12,16,19,20,21,22].
There is increasing evidence that anthropogenic land use changes can directly and indirectly influence vector-borne pathogen transmission dynamics
[10][23][10,23]. Although land use changes, such as urbanization as a result of forest degradation and deforestation, have been associated with increased disease transmission, their direction, extent, specific mechanisms, and persistence are not clearly understood. Often the effects of these factors on VBD emergence and resurgence are interdependent, synergistic, and difficult to study.
Central America is the region that links North and South America comprising most of the narrow isthmus that separates the Pacific Ocean from the Caribbean Sea. It consists of the countries of Belize, Costa Rica, Guatemala, El Salvador, Honduras, Panama, and Nicaragua, and is inhabited by about 44.5 million people. Generally, this region is characterized by a diversity of ecosystems, physical geographies, sociocultural and socioeconomic structures, and public health profiles
[24]. Over the past decades, this region has sustained dramatic land use changes, including cattle ranching, large-scale commercial plantations, illegal airstrips, mining, road construction, tourism infrastructure, illegal timber extraction, and housing construction. These land use changes have significantly accelerated the rates of deforestation and urbanization in the region
[25][26][27][28][29][30][25,26,27,28,29,30]. Despite the high prevalence of several VBDs in Central America, the effects of anthropogenic-driven deforestation and urbanization on the transmission dynamics of these diseases are not well understood. The presence and interactions of numerous physical and socioeconomic factors in the region amplifies its vulnerability to the emergence and resurgence of several VBDs
[6].
2. Mosquito-Borne and Tick-Borne Diseases in Central America
The global emergence and resurgence of VBDs in the last three decades are closely linked to demographic, economic, and societal changes. The decay in public health infrastructure required to prevent and control these diseases and the unprecedented population growth, primarily in rapidly growing cities, are factors that have facilitated VBD transmission and their geographic spread
[2][5][2,5]. In Central America, the most important VBDs affecting humans and animals include Chagas disease, leishmaniasis, dengue fever, malaria, Zika fever, chikungunya fever, West Nile fever, rickettsial diseases, Eastern equine encephalitis, Saint Louis encephalitis, and Venezuelan equine encephalitis (
Table 12)
[6][31][6,72].
Table 12. Description of the most important mosquito-borne and tick-borne diseases in Central America.
Disease |
Causative Agents |
Distribution of Infections in Humans |
Confirmed or Suspected Mosquitoes and/or Tick Vectors |
Confirmed or Suspected Non-Human Vertebrate Hosts |
West Nile fever |
West Nile virus (Flavivirus) |
Clinical, serosurveys (CR, N) |
Culex quinquefasciatus, Cx. mollis/Cx. inflictus (G) |
Equines, non-human primates, wild birds, sentinel chickens (CR, B, ES, G) |
Saint Louis encephalitis |
Saint Louis encephalitis virus (Flavivirus) |
Clinical, serosurveys (P, B, G, H) |
Sabethes chloropterus, Trichoposopon spp., Wyeomyia spp., Haemagogus lucifer, Deinocerites pseudes, Mansonia dyari, Culex nigripalpus (P, CR, G) |
Wild rodents, wild birds, sentinel rodents, sentinel chickens, non-human primates, sloths, equines, pigs (P, CR, B, H, G) |
Venezuelan equine encephalitis |
Venezuelan equine encephalitis virus (Alphavirus) |
Clinical, serosurveys (all countries) |
Psorophora confinnis, Culex nigripalpus, * Cx. (Melanoconion) taeniopus, other Cx. (Melanoconion) spp., Mansonia titillans, Ps. cilipes, Aedes taeniorhynchus, and Deinocerites pseudes (P, CR, B, G) |
Equines, wild rodent, opossum, birds, and bats (CR, N, H, ES, G) |
Eastern equine encephalitis |
Madariaga virus (Alphavirus) |
Clinical, serosurveys (P) |
Culex (Mel.) taeniopus (P) |
Horses, bats, wild lizards, wild birds (P, CR, B) |
Yellow fever |
Yellow fever virus (Flavivirus) |
Clinical (all countries) |
Aedes aegypti, Haemagogus janthinomys, Hg. leucocelaenus, Hg. lucifer, Hg. equinus, Hg. spegazzinii, and Sa. chloropterus, Hg. mesodentatus (P, CR, N, G) |
Non-human primates, marsupials (P, CR, N, B, H, G) |
Zika fever |
Zika virus (Flavivirus) |
Clinical and serological (all countries) |
** Aedes aegypti, Ae. albopictus (all countries) |
Unknown |
Chikungunya fever |
Chikungunya virus (Alphavirus) |
Clinical and serological (all countries) |
** Aedes aegypti, Ae. albopictus (all countries) |
Unknown |
Dengue fever |
Dengue viruses 1–4 (Flavivirus) |
Clinical and serological (all countries) |
** Aedes aegypti, Ae. albopictus (suspected) (all countries) |
Bats, non-human primates (CR) |
Mayaro fever |
Mayaro virus (Alphavirus) |
Clinical and serological (P, CR, G) |
Haemagogus janthinomys, Psorophora ferox, Culex (Mel.) vomerifer (P) |
Non-human primates (P, CR, H, G) |
Malaria |
Plasmodium vivax, P. falciparum |
Clinical and serological (all countries) |
* Anopheles albimanus, An. darlingi, An. punctimacula, other Anopheles spp. (all countries) |
Unknown |
|
P. malariae |
Clinical and serological (P, CR, B, ES, G) |
Unknown |
Unknown |
Rickettsiosis |
Rickettsia spp. (species causing spotted fevers was not identified) |
Clinical, serosurveys (all countries) |
Amblyomma mixtum (G) |
Wild rabbits, dogs, coyote (P, CR) |
|
R. rickettsii (Rocky Mountain spotted fever) |
Clinical (P, CR) |
* A. mixtum, Rhipicephalus sanguineus s.l., A. varium, Dermacentor nitens, Haemaphysalis leporispalustris (P, CR) |
Dog, horse (P, CR) |
|
R. akari (rickettsialpox) |
Serosurvey (CR) |
Unknown |
Unknown |
|
R. parkeri |
Unknown |
* A. maculatum (B) |
Unknown |
|
R. parkeri strain Atlantic Forest |
Unknown |
* A. ovale (B) |
Unknown |
|
R. africae |
Unknown |
A. ovale (N) |
Unknown |
Ehrlichiosis |
Ehrlichia chaffeensis (monocytic ehrlichiosis) |
Clinical (CR) |
Amblyoma mixtum, Amblyomma sp., Dermacentor nitens, Rhipicephalus microplus (P) |
Unknown |
|
E. ewingii (monocytic ehrlichiosis) |
Unknown |
R. microplus (P) |
Unknown |
|
E. canis (granulocytic ehrlichiosis) |
Clinical (P, CR) |
** R. sanguineus s.l. (all countries) |
Dogs (all countries) |
Anaplasmosis |
Anaplasma phagocytophilum (human granulocytic anaplasmosis) |
Unknown |
Rhipicephalus sanguineus s.l., R. microplus (P, CR) |
Dogs, bovines, equines, deer (CR, N, G) |
Borreliosis |
Borrelia burgdorferi s.l. (Lyme disease) |
Clinical (CR) |
Ixodes c.f. boliviensis (P) |
Dogs (CR) |
|
Borrelia sp. (tick-borne relapsing fever) |
Clinical (P, G) |
Ornithodoros talaje, O. rudis (P) |
Armadillos, opossums (P) |